Last edition
News about
CSIR-NIScPR appoints Dr Geetha Vani Rayasam as New Director
In her new role as CSIR-National Institute of Science Communication and Policy Research (NIScPR), Dr Geetha Vani Rayasam calls for agile Science, Technology and Innovation (STI) policies, future-ready science communication and stronger global collaborations.
Sun Pharma Halol Facility Classified OAI by US FDA, Shipments Restricted
The US Food and Drug Administration (FDA) has classified Sun Pharma's Halol facility as “Official Action Indicated” (OAI) following an inspection conducted between June 2 and June 13, 2025.
Lilly Drug Jaypirca Delivers Positive Results in CLL Patients
Lilly’s Jaypirca showed a strong Progression-Free Survival (PFS) benefit in front-line CLL, with data from BRUIN studies set to support global label expansion filings.
CDSCO Invites Recommendations on Braille Labelling and QR Code Features for Medicine Packaging
The Central Drugs Standard Control Organization (CDSCO) has begun discussions on mandating Braille labelling on medicine strips to help visually impaired individuals identify medicines and read key details like expiry dates.
DHL to Bolster Healthcare Logistics Portfolio with SDS Rx Acquisition
SDS Rx acquisition will mark the second healthcare purchase for DHL Supply Chain in 2025, following its purchase of CryoPDP earlier this year.
Eli Lilly Manufactures Access to AI-Powered Drug Discovery with Launch of TuneLab Platform
The initiative allows smaller biotechnology firms to utilise AI models developed from over a billion dollars of Eli Lilly’s proprietary research—historical investment that has yielded vast datasets derived from experiments on hundreds of thousands of unique molecules.
Morepen Medipath, Bimedical FZE Form Joint Venture to Foray into Medical Devices
Morepen Medipath (MML), a subsidiary of Morepen Laboratories, has signed a joint venture agreement with UAE-based Bimedical FZE to establish a new company in India focused on the medical devices sector.
AstraZeneca Rolls Out Anti-Complement Therapy for aHUS and PNH
AstraZeneca India launches Eculizumab (300 mg, 10 mg/ml), the first approved anti-complement therapy in India for the treatment of atypical Haemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH), following CDSCO approval in January 2025 for import, sale and distribution.
LB Pharmaceuticals Seeks 322 Million USD Valuation in Rare Biotech IPO Amid Market Slowdown
LB Pharmaceuticals, a cash-strapped drug developer, is targeting a valuation of up to 322 million USD (approximately 295 million EURO) in its upcoming New York initial public offering, which could become the first significant biotech listing in several months.
FDA Launches 'Green List' to Crack Down on Illegal GLP-1 API Imports
The US Food and Drug Administration (FDA) has created a new “green list” import alert to stop potentially dangerous GLP-1 (glucagon-like peptide-1) active pharmaceutical ingredients (APIs) from unverified foreign sources from entering the US market.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy